ReviewAmino acids2026
Spermidine in Colorectal cancer: friend or foe?
Review in Amino acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality, and its incidence is rising among individuals, especially young, underscoring the need for novel therapeutic strategies. CRC development is driven by genetic and epigenetic alterations in key oncogenic pathways and is accompanied by profound reprogramming of polyamine metabolism. In this context, spermidine (SPD), a central polyamine produced downstream of the MYC-ODC axis, is regarded as a pro-tumorigenic metabolite that sustains CRC growth by fueling eIF5A hypusination and MYC translation, thereby establishing a feed-forward MYC-ODC-polyamine-eIF5A circuit that promotes tumorigenesis. Recent studies also show that combined inhibition of polyamine biosynthesis and eIF5A hypusination synergistically impairs MYC translation and suppresses CRC growth in preclinical models, outperforming single-agent strategies such as ornithine decarboxylase (ODC) blockade with difluoromethylornithine (DFMO) and highlighting the translational potential of dual targeting of this axis. Conversely, other lines of evidence indicate that excessive SPD or altered flux through the polyamine pathway can be cytotoxic: multiple reports demonstrate that high-dose SPD triggers apoptosis, while experimental models suggest that SPD and epithelial eIF5A hypusination can protect against colitis and colitis-associated cancer by supporting the translation of detoxifying enzymes. Overall, the literature points to a dual role of SPD, and the aim of this review is to dissect the functions of SPD in CRC, to summarize and critically discuss the potential benefits of this polyamine, and to evaluate how it might be rationally exploited as a therapeutic agent in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.